89Zr-Trastuzumab_IJB

DRUG2 trials

Sponsors

Institut Jules Bordet

Conditions

advanced/metastatic HER2-positive breast carcinoma

Phase 2

HER2 molecular imaging with 89Zr-trastuzumab PET/CT as a predictive biomarker for antibody-drug conjugate sequencing in patients with advanced HER2-positive breast cancer

WithdrawnCTIS2024-516253-49-00

Institut Jules Bordetadvanced/metastatic HER2-positive breast carcinoma

Target: 31Updated: 2025-02-10

HER2 molecular imaging with 89Zr-trastuzumab PET/CT as a predictive biomarker for antibody-drug conjugate sequencing in patients with advanced HER2-positive breast cancer

RecruitingCTIS2024-516253-49-01

Institut Jules Bordetadvanced/metastatic HER2-positive breast carcinoma

Start: 2025-12-12Target: 72Updated: 2025-09-29